The National Patient Safety Foundation’s think tank, the NPSF Lucian Leape Institute, said today it received a $1 million grant from Medtronic (NYSE:MDT) to support the institute’s goals of improving patient safety. The grant is set to be distributed over 3 years, and was announced at the Annual NPSF Lucian Leape Institute forum & keynote […]
Medtronic
Medtronic touts CRT study showing heightened medication adherence
Patients implanted with cardiac resynchronization devices showed a greater rate of adherence to their medication regimens after their CRT devices were put it, according to a retrospective study Medtronic (NYSE:MDT) touted today. The analysis examined data from 4,512 patients who received CRT devices between January 2008 and December 2014, evaluating adherence to recommended medications before and […]
Diabetes: Medtronic touts JAMA study of closed-loop artificial pancreas
Medtronic (NYSE:MDT) said data from a study of its closed-loop hybrid artificial pancreas, published in the Journal of the American Medical Assn., showed that the system is safe and effectively maintained blood glucose levels within range in Type I diabetes patients age 14 and older. Results from the 3-month, 124-patient trial, also presented this week at […]
Japan approves Medtronic’s Reveal Linq cardiac monitor
Medtronic (NYSE:MDT) wasted no time in launching its Reveal Linq cardiac monitor in Japan, saying it plans to launch the device there this month now that the device won approval from the Ministry of Health, Labor & Welfare. The Reveal Linq device is designed to be implanted beneath the skin on the upper left side of […]
Ablative Solutions wins FDA nod for Phase II chemical denervation trial
Ablative Solutions said today that the FDA approved a Phase II trial of its chemical denervation system for hypertension under its investigational new drug application. The trial, called Target-BP I, will evaluate the efficacy of Ablative’s Peregrine infusion ablation system, which uses ethanol to interrupt signals from sympathetic nerves in the renal artery to control […]
NuVasive promotes Hannon to COO, Miles to vice chairman | Personnel Moves, Sept. 13, 2016
NuVasive promotes Hannon to COO, Miles to vice chairman NuVasive Inc. (NSDQ:NUVA) said today that it promoted Jason Hannon to be its new president & CEOO, replacing Patrick MIles, who ws named vice chairman. The San Diego-based spinal implant maker said the changes were effective Sept. 11. Hannon, formerly NuVasive’s international EVP, a purview he’ll keep. […]
FDA approves Medtronic’s In.Pact Admiral DCB for in-stent restenosis
Medtronic (NYSE:MDT) said today it won FDA premarket approval for its In.Pact Admiral drug-coated balloon with indications for treating in-stent restenosis in peripheral artery disease patients. The Fridley, Minn.-based medical device giant touted it as the 1st DCB to be cleared to treat ISR in the U.S., saying the approval was based on results from its In.Pact global study […]
Medtronic opens office in Vietnam
Medtronic (NYSE:MDT) said yesterday it opened a new office in Vietnam to greater serve the region. Fridley, Minn.-based Medtronic said it will “make important contributions” to fight cardiovascular diseases and cancer in the region, 2 of the highest contributors of non-communicable disease mortality in the region according to the World Health Organization. “Globalization is a […]
Masimo retools Nellcor royalty deal with Medtronic
Masimo (NSDQ:MASI) said today that it re-tooled the royalty agreement it won a decade ago after a $263 million patent infringement win over then-Tyco Healthcare subsidiary Nellcor, now owned by Medtronic (NYSE:MDT) after a series of corporate buyouts. The original settlement, inked back in January 2006, called for Nellcor to pay Masimo royalties on products using Masimo’s pulse […]
FDA approves Medtronic’s Enlite continuous glucose sensor
Medtronic (NYSE:MDT) said today that the FDA approved its Enlite sensor for the iPro2 Professional continuous glucose monitor. Medtronic said the Enlite device, a disposable sensor designed to be worn for 6 days, is 69% smaller than its previous sensor. The iPro2 Professional system is designed to track glucose levels every 5 minutes, 24 hours a day, for as long as 6 […]
Study: TAVR safer than surgery in low-risk heart failure patients
Transcatheter aortic valve replacement procedures with self-expanding systems resulted in higher survival rates for patients at lower risk for surgery when compared to surgical aortic valve replacement procedures, according to a study released this month. Results from the study, which compared Medtronic‘s (NYSE:MDT) self-expanding CoreValve TAVR system, were published in JAMA Cardiology this month. The retrospective […]